FIELD: medicine.
SUBSTANCE: invention concerns application of “Semax” peptide as agent, activating adaptive immunity for correction of immune status and elimination of imbalance inflammatory and anti-inflammatory effects in central nervous system diseases accompanied by disturbance of immune response, including stroke.
EFFECT: invention provides effect on immune system in ischemic stroke due to activation of acquired specific immunity.
1 cl, 1 ex, 3 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC INSULT AND METHOD FOR THERAPY | 2002 |
|
RU2251429C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| HYBRID PROTEIN IGF-1-LONG FOR TREATING STROKE, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2018 |
|
RU2711111C1 |
| METHOD OF TREATING CONDITIONS ASSOCIATED WITH A FACTOR INDUCED BY HYPOXIA (HIF) | 2015 |
|
RU2686308C2 |
| METHOD FOR TREATMENT OR PREVENTION OF STROKE | 2015 |
|
RU2744909C2 |
| ARTIFICIAL PEPTIDE FOR CRANIOCEREBRAL INJURY TREATMENT | 2023 |
|
RU2816919C1 |
| INJECTION DOSAGE FORM FOR TREATING ACUTE ISCHEMIC STROKE AND CRANIOCEREBERAL INJURY, METHOD FOR PREPARING AND USING | 2009 |
|
RU2431496C2 |
| METHOD FOR ASSESSMENT OF NEUROTROPHIN GENES EXPRESSION | 2009 |
|
RU2383619C1 |
| AGENT WITH NEUROPROTECTIVE ACTIVITY | 2019 |
|
RU2800955C2 |
| METHODS OF DIAGNOSING STROKE, EFFECTIVENESS OF THERAPY, AND DETERMINING RISK OF STROKE | 2019 |
|
RU2821748C2 |
